miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum

20 Dec 2018 - Yahoo News
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it will present new data from its Phase 1 trial of cobomarsen in HTLV-1 associated ...
usx:mgen

---

Hedge Funds Are Crazy About Miragen Therapeutics, Inc. (MGEN)

18 Dec 2018 - Yahoo News
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes ...
usx:mgen

---

miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman

5 Dec 2018 - Yahoo News
BOULDER, Colo., Dec. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Jeff Hatfield, a Director since 2017, as Chairman of the Board of Directors. ...
usx:mgen

---

miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides

2 Dec 2018 - Yahoo News
“We are excited to present final data from our Phase 1 cobomarsen clinical trial, which continue to show that cobomarsen is safe and well-tolerated, has relevant biological and clinical activity in patients and has the potential to impact the quality of life for MF patients,” stated miRagen Executive ...
usx:mgen

---

Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates

8 Nov 2018 - Nasdaq
Signal Genetics Inc MGEN came out with a quarterly loss of 0 29 per share versus the Zacks Consensus Estimate of a loss of 0 32 This compares to loss of 0 27 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings surprise
usx:mgen

---

Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Misses Revenue Estimates

7 Nov 2018 - Yahoo News
Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 9.38% and -50.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
usx:mgen

---

miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

7 Nov 2018 - Yahoo News
Continued advancements of three clinical stage microRNA-targeted product candidates currently being evaluated for multiple potential indications in four clinical trialsGlobal.
usx:mgen

---

Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting

1 Nov 2018 - Yahoo News
BOULDER, Colo., Nov. 01, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that new data from its Phase 1 trial of cobomarsen, an inhibitor of miR-155, in patients ...
usx:mgen

---

miRagen Therapeutics to Present at two Investor Conferences in November 2018

29 Oct 2018 - Yahoo News
BOULDER, Colo., Oct. 29, 2018 -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted.
usx:mgen

---

miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018

24 Oct 2018 - Yahoo News
BOULDER, Colo., Oct. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, November 7, 2018, at 4:30 p.m. ET to discuss its financial results ...
usx:mgen

---